Merck (MRK) Treasury Shares (2009 - 2026)
Merck (MRK) posted quarterly Treasury Shares of $63.7 billion for Q1 2026, up 7.32% year-over-year from $59.4 billion in Q1 2025, and up 1.19% quarter-over-quarter from $63.0 billion in Q4 2025.
Merck (MRK) Treasury Shares (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Treasury Shares for 18 consecutive years, with $1.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Treasury Shares rose 7.32% year-over-year to $63.7 billion; the TTM figure through Mar 2026 stood at $63.7 billion (up 7.32% YoY), while the FY2025 annual figure was $63.0 billion, up 8.05% from the prior year.
- Treasury Shares steadied at $1.1 billion in Q1 2026 per MRK's latest filing, from $1.1 billion in the prior quarter.
- Across five years, Treasury Shares topped out at $63.7 billion in Q1 2026 and bottomed at $56.5 billion in Q4 2022.
- Historically, Treasury Shares has averaged $58.5 billion across 5 years, with a median of $57.4 billion in 2024.
- Annual changes were most pronounced in 2022 — Treasury Shares slipped 1.09% — and 2025, when it grew 8.05%.
- Merck's Treasury Shares stood at $1.0 billion in 2022, then gained by 0.58% to $1.0 billion in 2023, then increased by 0.38% to $1.0 billion in 2024, then rose by 5.1% to $1.1 billion in 2025, then gained by 0.45% to $1.1 billion in 2026.
- Business Quant data shows MRK's Treasury Shares at $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 75.86 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 77.11 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.11 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 49.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 115.19 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.11 Bn |
| Jun 30, 2026 | 64.13 Bn |
| Jun 30, 2026 | 1.11 Bn |
| Jun 30, 2026 | 64.13 Bn |
| Mar 31, 2026 | 1.11 Bn |
| Mar 31, 2026 | 1.11 Bn |
| Mar 31, 2026 | 63.75 Bn |
| Mar 31, 2026 | 63.75 Bn |
| Dec 31, 2025 | 63.00 Bn |
| Dec 31, 2025 | 63.00 Bn |
| Dec 31, 2025 | 1.10 Bn |
| Dec 31, 2025 | 1.10 Bn |
| Sep 30, 2025 | 1.09 Bn |
| Sep 30, 2025 | 61.80 Bn |
| Sep 30, 2025 | 61.80 Bn |
| Sep 30, 2025 | 1.09 Bn |
| Jun 30, 2025 | 60.50 Bn |
| Jun 30, 2025 | 1.07 Bn |
| Jun 30, 2025 | 1.07 Bn |
| Jun 30, 2025 | 60.50 Bn |